SEC Form 4 · accession 0000899243-18-019566

Spero Therapeutics, Inc. · SPRO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — See Remarks · Director

Period of report

Jul 5, 2018

Accepted (ET)

Jul 6, 2018 · 9:41 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001701108

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F2	Jul 5, 2018	M	3,076	$5.90	A	68,893	D
Common Stock^F2	Jul 5, 2018	S	3,076	$17.6215	D	65,817	D
Common Stock^F2	Jul 6, 2018	M	1,600	$5.90	A	67,417	D
Common Stock^F2	Jul 6, 2018	S	500	$17.50	D	66,917	D
Common Stock^F2	Jul 6, 2018	S	100	$17.545	D	66,817	D
Common Stock^F2	Jul 6, 2018	S	400	$17.58	D	66,417	D
Common Stock^F2	Jul 6, 2018	S	100	$17.62	D	66,317	D
Common Stock^F2	Jul 6, 2018	S	100	$17.705	D	66,217	D
Common Stock^F2	Jul 6, 2018	S	200	$17.90	D	66,017	D
Common Stock^F2	Jul 6, 2018	S	200	$17.92	D	65,817	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F3	$5.90	Jul 5, 2018	M	3,076	D	—	Jul 5, 2027	Common Stock	3,076	120,488	D
Stock Option (Right to Buy)^F3	$5.90	Jul 6, 2018	M	1,600	D	—	Jul 5, 2027	Common Stock	1,600	118,888	D

F1The option exercises and related sales (totaling 4,676 shares) reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017.
F2Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.
F3All shares underlying this option were fully vested as of July 6, 2017.

Chief Executive Officer and President